BioNTech (NasdaqGS:BNTX) has started five additional pivotal oncology trials in collaboration with Bristol Myers Squibb. The company has expanded its oncology pipeline with new candidates entering later stage development.

BioNTech is planning site closures affecting up to 1,860 jobs and will buy back $1 billion in shares after announcing the departure of its co-founders. Production of its COVID-19 vaccine will be transferred to Pfizer,

Five additional pivotal trials for pumitamig initiated during 2026 in collaboration with Bristol Myers SquibbOncology pipeline strength and

BioNTech, once celebrated for its COVID-19 vaccines, is grappling with falling demand, restructuring and the departure of its founders. Can its ambitious cancer trials turn it from a one-hit wonder into a biotech giant?

A German government ​spokesperson said on ‌Wednesday that the loss of ​BioNTech vaccine ​production in the country ⁠can be ​offset by other ​companies.

Germany s BioNTech said Tuesday it will halt operations at several sites, in a move affecting up to 1,860 jobs, as sales of its

The action affects BioNTech sites in Germany and Singapore, where the company expects to have excess capacity.

The German company that pioneered one of the first mRNA coronavirus vaccines is halting production, handing the reins to partner Pfizer. BioNTech is restructuring to focus on research and illnesses like cancer.

The German biotech is struggling to redefine itself post-Covid, and an oncology push is part of the solution.